Compare BEEP & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEEP | VANI |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.1M | 111.0M |
| IPO Year | 2021 | 2014 |
| Metric | BEEP | VANI |
|---|---|---|
| Price | $2.58 | $1.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $5.83 | $3.83 |
| AVG Volume (30 Days) | 24.3K | ★ 121.7K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,075,000.00 | $4,000,000.00 |
| Revenue This Year | $1.47 | N/A |
| Revenue Next Year | $11.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.29 | $0.92 |
| 52 Week High | $3.78 | $1.81 |
| Indicator | BEEP | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 36.97 |
| Support Level | $2.54 | $1.10 |
| Resistance Level | $3.07 | $1.12 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 45.38 | 16.63 |
Mobile Infrastructure Corp focus on acquiring, owning and optimizing parking facilities and related infrastructure, including parking lots, parking garages, and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provides access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.